The new test could help identify which patients are most likely to benefit from new Alzheimer’s drugs. A newly developed ...

In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable ...

The prothrombin complex concentrate costs more than plasma, but may pay dividends by way of fewer adverse events.

A new consensus paper provides an updated evaluation of reference bone turnover markers (BTMs) and newer markers in the ...